Investigational and Comparative Study in the Management of Diabetic Nephropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

September 1, 2023

Conditions
Diabetic Nephropathy Type 2
Interventions
DRUG

Tadalafil 20Mg Oral Tablet

Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia

DRUG

Pentoxifylline 400 MG Oral Tablet

Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow

Trial Locations (1)

Unknown

Faculty of pharmacy, Tanta

All Listed Sponsors
lead

Tanta University

OTHER